BridgeBio Oncology Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Assets
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Increase (Decrease) in Other Noncurrent Assets of $228.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $1.56M, a 402.26% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$1.33M, a 4387.10% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $7.18M.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $57.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $228.00K 10-Q · filed 2026-08-11 | $7.41M derived: sum of 3 quarters · filed 2026-08-11 | $7.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.33M 10-Q · filed 2026-05-12 | $5.85M derived: sum of 2 quarters · filed 2026-05-12 | $5.91M derived: sum of 3 quarters · filed 2026-05-12 | $6.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $7.18M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $7.24M derived: sum of 2 quarters · filed 2026-04-30 | $7.55M derived: sum of 3 quarters · filed 2026-08-11 | $7.58M POS AM · filed 2026-04-30 |
| 2025-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $367.00K derived: sum of 2 quarters · filed 2026-08-11 | $398.00K 10-Q · filed 2025-11-12 | $389.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $310.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $341.00K 10-Q · filed 2026-08-11 | $332.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $31.00K 10-Q · filed 2026-05-12 | $22.00K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$9.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $3.58M POS AM · filed 2026-04-30 | ||
| 2024-09-30 | $3.58M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |